Clinical Trial Update: EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction [Phase 4]

View source ↗

Summary

Phase 4 EVOLVE-MI trial evaluating evolocumab very early after acute myocardial infarction; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Myocardial Infarction
• Stroke

Drugs mentioned

• Repatha (Evolocumab)

Snippet

Sponsor: Amgen | Conditions: Cardiovascular Disease, Myocardial Infarction | Phase 4 | Status: ACTIVE_NOT_RECRUITING